James L Mohler

List of Publications by Year
in descending order

162 papers	7,889 citations	76196 40 h-index	56606 83 g-index
167 all docs	167 docs citations	167 times ranked	9400 citing authors

#	Article	IF	Citations
1	Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24. Prostate Cancer and Prostatic Diseases, 2022, 25, 229-237.	2.0	9
2	Cholesterol-Lowering Intervention Decreases mTOR Complex 2 Signaling and Enhances Antitumor Immunity. Clinical Cancer Research, 2022, 28, 414-424.	3.2	14
3	A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry. European Urology, 2022, 81, 458-462.	0.9	22
4	5â€Alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia. Journal of Pathology, 2022, 256, 427-441.	2.1	28
5	Neighborhood deprivation and risk of mortality among men with prostate cancer: Findings from a longâ€term followâ€up study. Prostate, 2022, , .	1.2	10
6	Prediction of Incontinence after Robot-Assisted Radical Prostatectomy: Development and Validation of a 24-Month Incontinence Nomogram. Cancers, 2022, 14, 1644.	1.7	10
7	Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. European Urology, 2022, 82, 341-351.	0.9	32
8	Recreational and occupational physical activity in relation to prostate cancer aggressiveness: the North Carolina-Louisiana Prostate Cancer Project (PCaP). Cancer Causes and Control, 2022, , .	0.8	1
9	Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage Prostate Cancer: The Menâ€™s Eating and Living Study (Cancer and Leukemia Group 70807 [Alliance]). European Urology Focus, 2022, 8, 1607-1616.	1.6	1
10	Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5â€alpha reductase inhibitor treated human benign prostate hyperplasia patients. Prostate, 2022, 82, 1378-1388.	1.2	7
11	High intratumoral CD8⁺ Tâ€cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy. Prostate, 2021, 81, 20-28.	1.2	43
12	Africanâ€specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. International Journal of Cancer, 2021, 148, 99-105.	2.3	24
13	Oncologic outcome of radical prostatectomy versus radiotherapy as primary treatment for high and very high risk localized prostate cancer. Prostate, 2021, 81, 223-230.	1.2	6
14	Differential Associations of SLCO Transporters with Prostate Cancer Aggressiveness between African Americans and European Americans. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 990-999.	1.1	4
15	Identification of Plasma Glycosphingolipids as Potential Biomarkers for Prostate Cancer (PCa) Status. Biomolecules, 2020, 10, 1393.	1.8	12
16	Pictetâ€“Spengler condensations using 4-(2-aminoethyl)coumarins. New Journal of Chemistry, 2020, 44, 13415-13429.	1.4	4
17	Understanding the Relationship between Environmental Arsenic and Prostate Cancer Aggressiveness among African-American and European-American Men in North Carolina. International Journal of Environmental Research and Public Health, 2020, 17, 8364.	1.2	6
18	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. European Urology, 2020, 78, 316-320.	0.9	32

#	Article	IF	Citations
19	A CD24â€“p53 axis contributes to African American prostate cancer disparities. Prostate, 2020, 80, 609-618.	1.2	11
20	Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer. JAMA - Journal of the American Medical Association, 2020, 323, 140.	3.8	36
21	Prostate tumorâ€“derived GDF11 accelerates androgen deprivation therapyâ€“induced sarcopenia. JCI Insight, 2020, 5, .	2.3	6
22	Prevalence and predictors of probable depression in prostate cancer survivors. Cancer, 2019, 125, 3418-3427.	2.0	32
23	Patterns and predictors of selfâ€reported clinical diagnosis and treatment for depression in prostate cancer survivors. Cancer Medicine, 2019, 8, 3648-3658.	1.3	11
24	Association among plasma 1,25(OH) 2 D, ratio of 1,25(OH) 2 D to 25(OH)D, and prostate cancer aggressiveness. Prostate, 2019, 79, 1117-1124.	1.2	19
25	Cytochrome c Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer. Cancer Research, 2019, 79, 1353-1368.	0.4	22
26	Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy. Oncogene, 2019, 38, 4496-4511.	2.6	8
27	In honor of Dr. Donald S. Coffey â€“ Prostate cancer biology and therapy. Asian Journal of Urology, 2019, 6, 1-2.	0.5	0
28	Dietary patterns based on the Mediterranean diet and DASH diet are inversely associated with high aggressive prostate cancer in PCaP. Annals of Epidemiology, 2019, 29, 16-22.e1.	0.9	32
29	Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series. Prostate Cancer and Prostatic Diseases, 2019, 22, 309-316.	2.0	14
30	Potential impact of combined inhibition of 3Î±-oxidoreductases and 5Î±-reductases on prostate cancer. Asian Journal of Urology, 2019, 6, 50-56.	0.5	9
31	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 479-505.	2.3	943
32	Current recommendations for prostate cancer genetic testing: NCCN prostate guideline. Canadian Journal of Urology, 2019, 26, 34-37.	0.0	5
33	Statin use, high cholesterol and prostate cancer progression; results from HCaPâ€NC. Prostate, 2018, 78, 857-864.	1.2	7
34	Efficient synthesis of aurone Mannich bases and evaluation of their antineoplastic activity in PC-3 prostate cancer cells. Chemical Papers, 2018, 72, 2443-2456.	1.0	13
35	Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU International, 2018, 121, 534-539.	1.3	13
36	Serumâ€free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models. Prostate, 2018, 78, 213-221.	1.2	8

#	Article	IF	Citations
37	The association of metformin use with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study. Cancer Causes and Control, 2018, 29, 1143-1150.	0.8	3
38	A Direct Synthesis of 2â€(ï‰â€Carboxyalkyl)isoflavones from orthoâ€Hydroxylated Deoxybenzoins. European Journal of Organic Chemistry, 2018, 2018, 5460-5463.	1.2	4
39	Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nature Communications, 2018, 9, 3600.	5.8	96
40	Development of a Patient-Based Model for Estimating Operative Times for Robot-Assisted Radical Prostatectomy. Journal of Endourology, 2018, 32, 730-736.	1.1	8
41	NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 620-623.	2.3	236
42	Mathematical modeling of intracrine androgen metabolism in prostate cancer: Methodological aspects. Prostate, 2018, 78, 1069-1076.	1.2	2
43	Proteomic Analysis of Charcoal-Stripped Fetal Bovine Serum Reveals Changes in the Insulin-like Growth Factor Signaling Pathway. Journal of Proteome Research, 2018, 17, 2963-2977.	1.8	26
44	Modelling attrition and nonparticipation in a longitudinal study of prostate cancer. BMC Medical Research Methodology, 2018, 18, 60.	1.4	16
45	Inhibition of dihydrotestosterone synthesis in prostate cancer by combined frontdoor and backdoor pathway blockade. Oncotarget, 2018, 9, 11227-11242.	0.8	11
46	A brief history of intracrine androgen metabolism by castration-recurrent prostate cancer. American Journal of Clinical and Experimental Urology, 2018, 6, 101-106.	0.4	5
47	The Association of Diabetes and Obesity With Prostate Cancer Progression: HCaPâ€NC. Prostate, 2017, 77, 878-887.	1.2	12
48	Blinded review of archival radical prostatectomy specimens supports that contemporary Gleason score 6 prostate cancer lacks metastatic potential. Prostate, 2017, 77, 1076-1081.	1.2	6
49	Tobacco use and outcome in radical prostatectomy patients. Cancer Medicine, 2017, 6, 857-864.	1.3	5
50	Development and Validation of an Objective Scoring Tool for Robot-Assisted Radical Prostatectomy: Prostatectomy Assessment and Competency Evaluation. Journal of Urology, 2017, 197, 1237-1244.	0.2	46
51	Development, validation and clinical application of Pelvic Lymphadenectomy Assessment and Completion Evaluation: intraoperative assessment of lymph node dissection after robotâ€assisted radical cystectomy for bladder cancer. BJU International, 2017, 119, 879-884.	1.3	16
52	Developing antineoplastic agents that target peroxisomal enzymes: cytisine-linked isoflavonoids as inhibitors of hydroxysteroid 17-beta-dehydrogenase-4 (HSD17B4). Organic and Biomolecular Chemistry, 2017, 15, 7623-7629.	1.5	24
53	Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators. European Urology, 2017, 71, 183-192.	0.9	171
54	Lipid degradation promotes prostate cancer cell survival. Oncotarget, 2017, 8, 38264-38275.	0.8	64

#	Article	IF	Citations
55	A four gene signature predictive of recurrent prostate cancer. Oncotarget, 2017, 8, 3430-3440.	0.8	14
56	Carotenoid intake and adipose tissue carotenoid levels in relation to prostate cancer aggressiveness among African-American and European-American men in the North Carolina-Louisiana prostate cancer project (PCaP). Prostate, 2016, 76, 1053-1066.	1.2	19
57	Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line. Prostate, 2016, 76, 1067-1077.	1.2	9
58	Clinical significance of prospectively assigned Gleason tertiary pattern 4 in contemporary Gleason score 3+3=6 prostate cancer. Prostate, 2016, 76, 715-721.	1.2	14
59	Evolving Use of Androgen Deprivation Therapy in Prostate Cancer Management. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 663-665.	2.3	4
60	Validation of the Kattan Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1395-1401.	2.3	21
61	Statin Use and Prostate Cancer Aggressiveness: Results from the Population-Based North Carolinaâ€“Louisiana Prostate Cancer Project. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 670-677.	1.1	17
62	Intake of dietary antioxidants is inversely associated with biomarkers of oxidative stress among men with prostate cancer. British Journal of Nutrition, 2016, 115, 68-74.	1.2	20
63	Development and Validation of a Quality Assurance Score for Robot-assisted Radical Cystectomy: A 10-year Analysis. Urology, 2016, 97, 124-129.	0.5	30
64	The association of diabetes and obesity with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study. Cancer Causes and Control, 2016, 27, 1475-1485.	0.8	10
65	Characterization of Prostate Cancer in a Functional Eunuch. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1054-1060.	2.3	7
66	Regulators of Androgen Action Resource: a one-stop shop for the comprehensive study of androgen receptor action. Database: the Journal of Biological Databases and Curation, 2016, 2016, .	1.4	20
67	Outcomes of Scheduled vs For-Cause Biopsy Regimens for Prostate Cancer Active Surveillance. Journal of Urology, 2016, 196, 1061-1068.	0.2	3
68	Antineoplastic Isoflavonoids Derived from Intermediate orthoâ€Quinone Methides Generated from Mannich Bases. ChemMedChem, 2016, 11, 600-611.	1.6	19
69	Dietary Total Antioxidant Capacity is Inversely Associated with Prostate Cancer Aggressiveness in a Population-Based Study. Nutrition and Cancer, 2016, 68, 214-224.	0.9	23
70	Unit Nonresponse in a Population-Based Study of Prostate Cancer. PLoS ONE, 2016, 11, e0168364.	1.1	4
71	The essential role of methylthioadenosine phosphorylase in prostate cancer. Oncotarget, 2016, 7, 14380-14393.	0.8	29
72	Dietary, supplement, and adipose tissue tocopherol levels in relation to prostate cancer aggressiveness among African and European Americans: The North Carolina-Louisiana Prostate Cancer Project (PCaP). Prostate, 2015, 75, 1419-1435.	1.2	12

#	Article	IF	Citations
73	Impact of devascularization and tissue procurement on cell number and RNA integrity in prostatectomy tissue. Prostate, 2015, 75, 1910-1915.	1.2	4
74	Association between Plasma 25-Hydroxyvitamin D, Ancestry and Aggressive Prostate Cancer among African Americans and European Americans in PCaP. PLoS ONE, 2015, 10, e0125151.	1.1	22
75	Thioredoxin 1 in Prostate Tissue Is Associated with Gleason Score, Erythrocyte Antioxidant Enzyme Activity, and Dietary Antioxidants. Prostate Cancer, 2015, 2015, 1-8.	0.4	8
76	Application of Mannich bases to the synthesis of hydroxymethylated isoflavonoids as potential antineoplastic agents. Organic and Biomolecular Chemistry, 2015, 13, 11292-11301.	1.5	18
77	Surgical Competency for Urethrovesical Anastomosis During Robot-assisted Radical Prostatectomy: Development and Validation of the Robotic Anastomosis Competency Evaluation. Urology, 2015, 85, 27-32.	0.5	49
78	Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer. European Urology, 2015, 67, 53-60.	0.9	205
79	Roles for the Backdoor Pathway of Androgen Metabolism in Prostate Cancer Response to Castration and Drug Treatment. International Journal of Biological Sciences, 2014, 10, 596-601.	2.6	23
80	Androgenic biomarker profiling in human matrices and cell culture samples using high throughput, electrospray tandem mass spectrometry. Prostate, 2014, 74, 722-731.	1.2	21
81	Sequential Use of the Androgen Synthesis Inhibitors Ketoconazole and Abiraterone Acetate in Castration-Resistant Prostate Cancer and the Predictive Value of Circulating Androgens. Clinical Cancer Research, 2014, 20, 6269-6276.	3.2	32
82	The Thoc1 Ribonucleoprotein and Prostate Cancer Progression. Journal of the National Cancer Institute, 2014, 106, dju306-dju306.	3.0	19
83	Concept and viability of androgen annihilation for advanced prostate cancer. Cancer, 2014, 120, 2628-2637.	2.0	16
84	5Î±â€reductase type 3 enzyme in benign and malignant prostate. Prostate, 2014, 74, 235-249.	1.2	36
85	Associations between patientâ€“provider communication and socio-cultural factors in prostate cancer patients: A cross-sectional evaluation of racial differences. Patient Education and Counseling, 2014, 97, 339-346.	1.0	39
86	Re: Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents. European Urology, 2014, 66, 597.	0.9	2
87	Mechanism of androgen receptor corepression by CKÎ²BP2/CRIF1, a multifunctional transcription factor coregulator expressed in prostate cancer. Molecular and Cellular Endocrinology, 2014, 382, 302-313.	1.6	9
88	A randomized trial of diet in men with early stage prostate cancer on active surveillance: Rationale and design of the Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]). Contemporary Clinical Trials, 2014, 38, 198-203.	0.8	27
89	Low Detectable Prostate Specific Antigen after Radical Prostatectomyâ€”Treat or Watch?. Journal of Urology, 2014, 192, 1390-1396.	0.2	15
90	Revisiting nomenclature for the description of prostate cancer androgen-responsiveness. American Journal of Clinical and Experimental Urology, 2014, 2, 121-6.	0.4	1

#	Article	IF	Citations
91	Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5Î±-reductase inhibitors. Prostate, 2013, 73, 1470-1482.	1.2	29
92	Melanoma Antigen-A11 (MAGE-A11) Enhances Transcriptional Activity by Linking Androgen Receptor Dimers. Journal of Biological Chemistry, 2013, 288, 1939-1952.	1.6	33
93	The direct inhibitory effect of dutasteride or finasteride on androgen receptor activity is cell line specific. Prostate, 2013, 73, 1483-1494.	1.2	13
94	Receipt of National Comprehensive Cancer Network guidelineâ€concordant prostate cancer care among African American and Caucasian American men in North Carolina. Cancer, 2013, 119, 2282-2290.	2.0	25
95	New Developments in the Management of Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 653-657.	2.3	16
96	The Role of Intracrine Androgen Metabolism, Androgen Receptor and Apoptosis in the Survival and Recurrence of Prostate Cancer During Androgen Deprivation Therapy. Current Drug Targets, 2013, 14, 420-440.	1.0	18
97	The 5 Alpha-Reductase Isozyme Family: A Review of Basic Biology and Their Role in Human Diseases. Advances in Urology, 2012, 2012, 1-18.	0.6	225
98	Ten Years of Progress in Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 136-140.	2.3	1
99	Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1081-1087.	2.3	208
100	Biology of Castration-Recurrent Prostate Cancer. Urologic Clinics of North America, 2012, 39, 435-452.	0.8	28
101	Role of 5Î±-Reductase Inhibitors in Prostate Cancer Prevention and Treatment. Urology, 2012, 79, 1197-1205.	0.5	40
102	Dominant-Negative Androgen Receptor Inhibition of Intracrine Androgen-Dependent Growth of Castration-Recurrent Prostate Cancer. PLoS ONE, 2012, 7, e30192.	1.1	6
103	Living WCRF Recommendations associated with less Prostate Cancer Aggressiveness among African and Caucasian Americans. FASEB Journal, 2012, 26, 388.4.	0.2	0
104	Use of Abiraterone for Prostate Cancer. Journal of Urology, 2011, 185, 783-786.	0.2	8
105	5Î±â€reductase type 3 expression in human benign and malignant tissues: A comparative analysis during prostate cancer progression. Prostate, 2011, 71, 1033-1046.	1.2	93
106	Potential Prostate Cancer Drug Target: Bioactivation of Androstanediol by Conversion to Dihydrotestosterone. Clinical Cancer Research, 2011, 17, 5844-5849.	3.2	65
107	Activation of the Androgen Receptor by Intratumoral Bioconversion of Androstanediol to Dihydrotestosterone in Prostate Cancer. Cancer Research, 2011, 71, 1486-1496.	0.4	135
108	Androgen deprivation induces rapid involution and recovery of human prostate vasculature. American Journal of Physiology - Endocrinology and Metabolism, 2011, 300, E263-E275.	1.8	44

#	Article	IF	Citations
109	INTRACRINE SYNTHESIS OF ANDROGENS BY PROSTATE CANCER IN RESPONSE TO ANDROGEN DEPRIVATION THERAPY. , 2011, , 193-218.		2
110	Title is missing!. Japanese Journal of Urology, 2011, 102, 341.	0.0	0
111	Survival advantage of AMPK activation to androgen-independent prostate cancer cells during energy stress. Cellular Signalling, 2010, 22, 1554-1561.	1.7	44
112	The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reduction. Cancer Biology and Therapy, 2010, 9, 1033-1042.	1.5	20
113	Editorial Comment. Journal of Urology, 2010, 183, 1797-1797.	0.2	0
114	Atmospheric Pressure Photoionization Tandem Mass Spectrometry of Androgens in Prostate Cancer. Analytical Chemistry, 2010, 82, 6000-6007.	3.2	26
115	Whole grain and dietary fiber intake and prostate cancer aggressiveness by race. FASEB Journal, 2010, 24, 729.2.	0.2	0
116	Increased Expression of Androgen Receptor Coregulator MAGE-11 in Prostate Cancer by DNA Hypomethylation and Cyclic AMP. Molecular Cancer Research, 2009, 7, 523-535.	1.5	112
117	14-3-3Î· Amplifies Androgen Receptor Actions in Prostate Cancer. Clinical Cancer Research, 2009, 15, 7571-7581.	3.2	13
118	Comparison of ACINUS, caspaseâ€3, and TUNEL as apoptotic markers in determination of tumor growth rates of clinically localized prostate cancer using image analysis. Prostate, 2009, 69, 1603-1610.	1.2	9
119	Phase II Study of Dutasteride for Recurrent Prostate Cancer During Androgen Deprivation Therapy. Journal of Urology, 2009, 181, 621-626.	0.2	54
120	Tissue Levels of Androgens in Castration-Recurrent Prostate Cancer. , 2009, , 553-568.		2
121	5Î±-Reductase Isozymes in Castration-Recurrent Prostate Cancer. , 2009, , 175-185.		1
122	A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 357-372.	2.2	36
123	Thioredoxin Reductase 1 Expression and Castration-recurrent Growth of Prostate Cancer. Translational Oncology, 2008, 1, 153-157.	1.7	21
124	Phenotype-Specific CpG Island Methylation Events in a Murine Model of Prostate Cancer. Cancer Research, 2008, 68, 4173-4182.	0.4	18
125	Castration-Recurrent Prostate Cancer Is Not Androgen-Independent. Advances in Experimental Medicine and Biology, 2008, 617, 223-234.	0.8	90
126	Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8438-8443.	3.3	223

#	Article	IF	Citations
127	Peroxiredoxin 1 Interacts with Androgen Receptor and Enhances Its Transactivation. Cancer Research, 2007, 67, 9294-9303.	0.4	78
128	Feasibility of constructing tissue microarrays from diagnostic prostate biopsies. Prostate, 2007, 67, 1011-1018.	1.2	13
129	Racial Differences in Prostate Cancer Mortality. , 2007, , 355-376.		1
130	Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability. Prostate, 2006, 66, 1292-1301.	1.2	129
131	The North Carolinaâ€“Louisiana Prostate Cancer Project (PCaP): Methods and design of a multidisciplinary population-based cohort study of racial differences in prostate cancer outcomes. Prostate, 2006, 66, 1162-1176.	1.2	63
132	Hypoxia Increases Androgen Receptor Activity in Prostate Cancer Cells. Cancer Research, 2006, 66, 5121-5129.	0.4	73
133	Breast Cancer Resistance Proteinâ€“Mediated Efflux of Androgen in Putative Benign and Malignant Prostate Stem Cells. Cancer Research, 2005, 65, 6640-6650.	0.4	119
134	Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer. Clinical Cancer Research, 2005, 11, 4653-4657.	3.2	457
135	Steroid 5Î±-Reductase Isozymes I and II in Recurrent Prostate Cancer. Clinical Cancer Research, 2005, 11, 4365-4371.	3.2	166
136	Activated Tyrosine Kinase Ack1 Promotes Prostate Tumorigenesis: Role of Ack1 in Polyubiquitination of Tumor Suppressor Wwox. Cancer Research, 2005, 65, 10514-10523.	0.4	186
137	Java Web Start based software for automated quantitative nuclear analysis of prostate cancer and benign prostate hyperplasia. BioMedical Engineering OnLine, 2005, 4, 31.	1.3	13
138	IL-15 The androgen axis in recurrent prostate cancer. Japanese Journal of Urology, 2004, 95, 280.	0.0	0
139	The Androgen Axis in Recurrent Prostate Cancer. Clinical Cancer Research, 2004, 10, 440-448.	3.2	629
140	RACIAL DIFFERENCES IN PROSTATE ANDROGEN LEVELS IN MEN WITH CLINICALLY LOCALIZED PROSTATE CANCER. Journal of Urology, 2004, 171, 2277-2280.	0.2	49
141	Expression of Annexin I, II and VII Proteins in Androgen Stimulated and Recurrent Prostate Cancer. Journal of Urology, 2004, 171, 916-920.	0.2	56
142	Sampling strategy for prostate tissue microarrays for Ki-67 and androgen receptor biomarkers. , 2004, 26, 194-200.		7
143	Apoptosis levels increase after castration in the CWR22 human prostate cancer xenograft. Prostate, 2003, 57, 24-31.	1.2	23
144	Androgen Receptor Gene Amplification and Protein Expression in Recurrent Prostate Cancer. Journal of Urology, 2003, 170, 1817-1821.	0.2	131

#	Article	IF	Citations
145	Racial Differences in Androgen Receptor Protein Expression in Men With Clinically Localized Prostate Cancer. Journal of Urology, 2003, 170, 990-993.	0.2	129
146	Androgen Receptor Expression and Cellular Proliferation During Transition from Androgen-Dependent to Recurrent Growth after Castration in the CWR22 Prostate Cancer Xenograft. American Journal of Pathology, 2002, 160, 219-226.	1.9	70
147	A novel method for the analysis of the androgen receptor. Current Urology Reports, 2002, 3, 67-74.	1.0	6
148	Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer. Prostate, 2002, 51, 247-255.	1.2	62
149	Androgen Receptor Up-Regulates Insulin-Like Growth Factor Binding Protein-5 (IGFBP-5) Expression in a Human Prostate Cancer Xenograft*. Endocrinology, 1999, 140, 2372-2381.	1.4	57
150	Immunohistochemical quantitation of androgen receptor expression using color video image analysis. Cytometry, 1999, 35, 2-10.	1.8	29
151	Overexpression of cyclin D1 is rare in human prostate carcinoma. , 1999, 38, 40-45.		46
152	Dehydroepiandrosterone Activates Mutant Androgen Receptors Expressed in the Androgen-Dependent Human Prostate Cancer Xenograft CWR22 and LNCaP Cells. Molecular Endocrinology, 1997, 11, 450-459.	3.7	306
153	Expectant management as an option for men with stage T1c prostate cancer: a preliminary study. World Journal of Urology, 1997, 15, 364-368.	1.2	16
154	The Role of Motility Proteins and Metastasisâ€Suppressor Genes in Prostate Cancer Progression. Stem Cells, 1996, 14, 508-516.	1.4	7
155	Genetic instability assessed by sister chromatid exchange analysis in the dunning R-3327 rat prostatic adenocarcinoma model and its relationship to metastatic potential. Prostate, 1995, 26, 247-252.	1.2	0
156	Editorial: Treatment Issues in Clinically Localized Prostatic Carcinoma. Journal of Urology, 1995, 154, 1433-1434.	0.2	3
157	Nuclear shape analysis for the assessment of local invasion and metastases in clinically localized prostate carcinoma. Cancer, 1994, 74, 2996-3001.	2.0	18
158	Collagen Cross-Link Metabolites in Urine as Markers of Bone Metastases in Prostatic Carcinoma. Journal of Urology, 1994, 151, 909-913.	0.2	53
159	Flow cytometric assay of pinocytosis: Correlation with membrane ruffling and metastatic potential in the dunning R-3327 rat prostatic adenocarcinoma model. Cytometry, 1993, 14, 826-831.	1.8	4
160	In vitro high resolution1h-spectroscopy of the human prostate: Benign prostatic hyperplasia, normal peripheral zone and adenocarcinoma. Magnetic Resonance in Medicine, 1993, 29, 285-291.	1.9	79
161	Immunohistochemistry of the Androgen Receptor in Human Benign and Malignant Prostate Tissue. Journal of Urology, 1993, 149, 1015-1019.	0.2	64
162	Prediction of prognosis in untreated stage A2 prostatic carcinoma. Cancer, 1992, 69, 511-519.	2.0	47